C
C. Tausch
Publications - 4
Citations - 921
C. Tausch is an academic researcher. The author has contributed to research in topics: Pertuzumab & Anthracycline. The author has an hindex of 3, co-authored 4 publications receiving 730 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,Roberto Hegg,C. Tausch,J.H. Seo,Y.-F. Tsai,Jayantha Ratnayake,V. McNally,Graham Ross,Javier Cortes +12 more
TL;DR: The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed.
Proceedings ArticleDOI
S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,Roberto Hegg,C. Tausch,J-H Seo,Y.-F. Tsai,A Ackrill,Graham Ross,J. Cortes +11 more
TL;DR: The NeoSphere study demonstrated significantly increased antitumor activity in the neoadjuvant setting for the combination of P and trastuzumab (H) plus docetaxel (T) compared with HT alone, consistent with the hypothesis of complementary mechanisms of action of P-H and H.
Journal ArticleDOI
Biomarker (BM) Analyses of a Phase II Study of Neoadjuvant Pertuzumab and Trastuzumab With and Without Anthracycline (ATC)-Containing Chemotherapy for Treatment of HER2-Positive Early Breast Cancer (BC) (Tryphaena)
Andreas Schneeweiss,Stephen Chia,Roberto Hegg,C. Tausch,R. Deb,Jayantha Ratnayake,Astrid Kiermaier,V. McNally,Graham Ross,J. Cortes +9 more
TL;DR: This analysis supports the use of HER2 overexpression as the strongest predictive and clinically relevant BM for pCR after treatment with H + P +-CT neoadjuvant regimen for pts with HER2-positive BC.
Journal ArticleDOI
192 Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA)
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Roberto Hegg,C. Tausch,J.H. Seo,Y.-F. Tsai,V. McNally,J. Cortes +9 more